Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.

Leukemia research - 1 Dec 2009

Beel Karolien, Janssens Ann, Verhoef Gregor, Vandenberghe Peter

Abstract excerpt

In this letter we describe two case reports of CML patients with acquired mutations of the BCR-ABL1 kinase domain, in whom the mutant clone regressed and drug sensitivity was restored after temporary interruption of TKI. We believe that temporary interruption of an ATP-competitive tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Administration Schedule
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ABL1 gene

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 19457553
DOI: 10.1016/j.leukres.2009.04.021

Genes

ABL1
BCR
CRKL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19457553-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.PMID 19457553Read ↗

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.Semantic proximity Read ↗

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.Semantic proximity Read ↗

Molecular monitoring in CML and the prospects for treatment-free remissions.Semantic proximity Read ↗

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Semantic proximity Read ↗

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationSemantic proximity Read ↗

Mechanisms and implications of imatinib resistance mutations in BCR-ABLSemantic proximity Read ↗

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaSemantic proximity Read ↗

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor RechallengeSemantic proximity Read ↗

A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.Semantic proximity Read ↗

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.Semantic proximity Read ↗

BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.